American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

J Med Toxicol. 2024 Jan;20(1):64-67. doi: 10.1007/s13181-023-00981-z. Epub 2023 Nov 30.

Authors

Andrew I Stolbach¹, Maryann Mazer-Amirshahi², Lewis S Nelson³, Jon B Cole⁴

Affiliations

¹ Johns Hopkins University School of Medicine, Baltimore, MD, USA. positionstatements@acmt.net.
² MedStar Washington Hospital Center, Washington, DC, USA.
³ Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
⁴ Minnesota Poison Control System, Departments of Emergency Medicine, Hennepin Healthcare and University of Minnesota Medical School, Minneapolis, MN, USA.

PMID: 38032431
PMCID: PMC10774510 (available on 2025-01-01)
DOI: 10.1007/s13181-023-00981-z

No abstract available

Keywords: FDA Abbreviated New Drug Application; Intranasal; Nalmefene; Naloxone; Opioid overdose.

MeSH terms

Analgesics, Opioid / adverse effects
Antidotes / therapeutic use
Drug Overdose* / diagnosis
Drug Overdose* / drug therapy
Humans
Naloxone* / therapeutic use
Naltrexone / therapeutic use
Narcotic Antagonists / therapeutic use
United States

Substances

Naloxone
nalmefene
Analgesics, Opioid
Antidotes
Naltrexone
Narcotic Antagonists